MedTrace Logo

Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment

NCT01122134 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2010-05-13

No results posted yet for this study

Summary

Intravenous artesunate is highly effective with rapid schizonticidal action and improved clinical outcome

Conditions

  • Severe Malaria

Interventions

DRUG

intravenous artesunate

Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.

Sponsors & Collaborators

  • Makerere University

    lead OTHER

Principal Investigators

  • Pauline Byakika-Kibwika, MSc, MMed · Makerere University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-08-31
Completion
2010-09-30

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01122134 on ClinicalTrials.gov